Table S1.
Histopathological findings, classified and clustered
| No | Findings | samples | Total samples | Samples/total (%) | UR average | UR SD | WHO-I | WHO-II | WHO-III | WHO-IV | Other | LGG | HGG | Patients | All Patients | Patients/all patients (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Coagulated blood | 12 | 363 | 3 | 1.4 | 0.5 | 0 | 0 | Yes | Yes | 0 | 0 | Yes | 4 | 23 | 17 |
| 2 | Diapedesis bleeding | 49 | 363 | 13 | 1.8 | 0.6 | 0 | Yes | Yes | Yes | Yes | Yes | Yes | 12 | 23 | 52 |
| 3 | Acute hemorrhage | 27 | 363 | 7 | 1.4 | 0.6 | 0 | Yes | Yes | Yes | Yes | Yes | Yes | 8 | 23 | 35 |
| 4 | Exudate | 3 | 363 | 1 | 1.4 | 0.4 | 0 | 0 | 0 | Yes | 0 | 0 | Yes | 1 | 23 | 4 |
| 5 | Only edema | 2 | 363 | 1 | 1.9 | 0.1 | 0 | 0 | 0 | Yes | 0 | 0 | Yes | 1 | 23 | 4 |
| 6 | Gliosis | 3 | 363 | 1 | 0.8 | 0 | 0 | 0 | 0 | 0 | Yes | 0 | 0 | 1 | 23 | 4 |
| 7 | Tissue-infiltration zone | 25 | 363 | 7 | 1.6 | 0.6 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 10 | 23 | 43 |
| 8 | Small cell presence | 69 | 363 | 19 | 1.1 | 0.6 | Yes | Yes | Yes | Yes | 0 | Yes | Yes | 10 | 23 | 43 |
| 9 | Moderate cell presence | 77 | 363 | 21 | 1.2 | 0.6 | Yes | Yes | Yes | Yes | 0 | Yes | Yes | 14 | 23 | 61 |
| 10 | Strong cell presence | 74 | 363 | 20 | 1.7 | 0.6 | Yes | Yes | Yes | Yes | 0 | Yes | Yes | 12 | 23 | 52 |
| 11 | Pathologic pattern of proliferation | 45 | 363 | 12 | 1.9 | 0.6 | 0 | 0 | 0 | Yes | 0 | 0 | Yes | 9 | 23 | 39 |
| 12 | Prominent blood vessels | 3 | 363 | 1 | 2.3 | 0.5 | 0 | 0 | Yes | Yes | 0 | 0 | Yes | 2 | 23 | 9 |
| 13 | Mitosis | 24 | 363 | 7 | 1.9 | 0.5 | 0 | 0 | Yes | Yes | 0 | 0 | Yes | 7 | 23 | 30 |
| 14 | Necrosis | 34 | 363 | 9 | 1.9 | 0.6 | 0 | 0 | 0 | Yes | 0 | 0 | Yes | 10 | 23 | 43 |
| 15 | GFAP | 23 | 363 | 6 | 1.5 | 0.6 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 21 | 23 | 91 |
| 16 | NogoA | 2 | 363 | 1 | 1.5 | 0.6 | 0 | Yes | 0 | 0 | 0 | Yes | 0 | 2 | 23 | 9 |
| 17 | MAP2 | 3 | 363 | 1 | 1.2 | 0.6 | 0 | Yes | 0 | 0 | 0 | Yes | 0 | 3 | 23 | 13 |
| 18 | Olig2 | 17 | 363 | 5 | 2.2 | 0.6 | 0 | 0 | 0 | Yes | 0 | 0 | Yes | 2 | 23 | 9 |
| 19 | p53 | 15 | 363 | 4 | 1.3 | 0.6 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 11 | 23 | 48 |
| 20 | Tibor PAP silver impregnation for reticulin | 13 | 363 | 4 | 1.3 | 0.6 | 0 | Yes | 0 | Yes | 0 | Yes | Yes | 5 | 23 | 22 |
| 21 | Vimentin | 2 | 363 | 1 | 1.5 | 0.2 | 0 | Yes | 0 | Yes | 0 | Yes | Yes | 2 | 23 | 9 |
| 22 | Strong gliosis | 3 | 363 | 1 | 2 | 0.1 | 0 | Yes | 0 | 0 | 0 | Yes | 0 | 1 | 23 | 4 |
| 23 | CNS with cell proliferation | 9 | 363 | 2 | 1.6 | 0.6 | 0 | Yes | Yes | 0 | Yes | Yes | Yes | 4 | 23 | 17 |
| 24 | Macrophages | 7 | 363 | 2 | 1.6 | 0.6 | 0 | Yes | Yes | 0 | Yes | Yes | Yes | 4 | 23 | 17 |
| 25 | LFP- or PAS positive myelin | 5 | 363 | 1 | 1.8 | 0.6 | 0 | Yes | 0 | 0 | 0 | Yes | 0 | 2 | 23 | 9 |
| 26 | Reactive changes | 7 | 363 | 2 | 1.3 | 0.6 | 0 | 0 | Yes | 0 | Yes | 0 | Yes | 2 | 23 | 9 |
| 27 | Lymphocyte infiltrates (TILs) | 6 | 363 | 2 | 1.3 | 0.6 | 0 | 0 | Yes | 0 | Yes | 0 | Yes | 2 | 23 | 9 |
Abbreviations: UR, uptake ratio; SD, standard deviation; LGG, low-grade glioma; HGG, high-grade glioma; WHO, World Health Organization; PAP, peroxidase–antiperoxidase; CNS, central nervous system; LFP, lateral fluid percussion; PAS, periodic acid–Schiff; TILs, tumor-infiltrating lymphocytes; No, number.